Skin & aging MC1R agonist
Afamelanotide
Regulatory status
Status at a glance
503A compounding status
Not nominated
We found no pending nomination for the 503A bulks list. Unless the substance has another legal pathway (for example, a USP monograph or use in an FDA-approved drug), 503A pharmacies generally may not compound with it.
- FDA approval
- An FDA-approved product contains this peptide
- 503B outsourcing
- Not determined
- Anti-doping (WADA)
- Not on the WADA Prohibited List
- DEA schedule
- Not a controlled substance
About peptide status
Most peptides discussed here are not FDA-approved for any use, and products labeled “research use only” are not for human use. Removal from Category 2 does not authorize compounding. PCAC votes are non-binding recommendations; FDA and HHS make the final decisions.
This is not medical or legal advice, and we do not publish dosing, sourcing or reconstitution information. Talk with a licensed clinician before using any peptide.
If you think you are having a medical emergency, call 911.
Key takeaway
Afamelanotide is a synthetic, longer-lasting analog of alpha-melanocyte-stimulating hormone (α-MSH) that activates the MC1R receptor on pigment cells to boost the skin's own protective eumelanin. The FDA approved it in 2019 as Scenesse, a subcutaneous implant for adults with erythropoietic protoporphyria (EPP), a rare light-sensitivity disorder. In the pivotal 2015 placebo-controlled trials, U.S. patients (94) logged a median 69.4 pain-free hours in direct sunlight versus 40.8 on placebo (P = 0.04). EU patients (74) logged 6.0 versus 0.8 hours (P = 0.005).
At a glance
- FDA status
- FDA-approved peptide, sold as Scenesse, given as a subcutaneous implant
- How it works
- Synthetic analog of α-MSH that activates the MC1R receptor to increase the skin's protective eumelanin pigment
- Approved for
- Increasing pain-free light exposure in adults with erythropoietic protoporphyria (EPP), a rare inherited photosensitivity disorder
- History
- Began as "Melanotan," a 1980s effort to create a protective sunless tan
- Evidence strength
- FDA approved
Summary
Afamelanotide is a synthetic form of a skin hormone, FDA-approved in 2019 as the Scenesse implant for adults with EPP. See how it works and what trials show.
What is afamelanotide?
Afamelanotide is a synthetic peptide that mimics alpha-melanocyte-stimulating hormone (α-MSH), the natural hormone that controls skin pigmentation. It is an analog engineered to be more potent and far longer-lasting than natural α-MSH, and it is also known by the research names Melanotan I and NDP-MSH. It is made by Clinuvel Pharmaceuticals and sold as Scenesse.
Rather than a daily injection, it is given as a small dissolvable implant placed just under the skin by a healthcare provider, which releases the drug slowly over several days.
The history of afamelanotide
Afamelanotide began as an attempt to bottle a sunless tan. In the 1980s, researchers Mac Hadley and Victor Hruby at the University of Arizona set out to design a synthetic version of α-MSH that could darken skin without sun exposure, reasoning that a drug-induced protective tan might lower skin cancer risk in a sun-drenched state like Arizona. Natural α-MSH breaks down too quickly to be practical, so they built a more stable, more potent analog and called it Melanotan.
The Arizona program actually produced two related compounds. Melanotan I, the linear analog, is what became afamelanotide. A second, cyclic analog called Melanotan II was pursued separately and eventually led to a different drug for sexual dysfunction.
The program then shifted from a cosmetic tanning agent to a medical photoprotectant for people with serious light-sensitivity disorders. That path led, over roughly two decades, to approval for erythropoietic protoporphyria (EPP), in the European Union in 2014 and the United States in 2019.
The original tanning idea never fully went away. Unapproved "Melanotan I" and "Melanotan II" peptides are still sold online as injectable tanning products, and regulators have repeatedly warned against them, because they are not approved, not quality-controlled, and not the same as the regulated implant.
How does afamelanotide work?
Afamelanotide works by switching on the skin's own pigment system to build a protective layer of melanin. It is a potent agonist of the melanocortin-1 receptor, or MC1-R, which sits on melanocytes, the pigment-producing cells of the skin.
Activating MC1R drives those cells to make more eumelanin, the dark form of melanin that acts as the body's natural sunscreen, absorbing and scattering light and neutralizing the reactive oxygen species that light can generate in the skin. Because the drug triggers this through the receptor rather than through sun exposure, it raises eumelanin without requiring the UV damage that normally produces a tan.
In erythropoietic protoporphyria, that extra pigment matters for a specific reason. People with EPP build up a molecule called protoporphyrin IX, which reacts with visible light to produce bursts of reactive oxygen that damage tissue and cause severe burning pain after even brief light exposure. By increasing eumelanin, afamelanotide reduces how much light reaches and reacts in the skin, which lengthens the time a person can spend in the light before pain begins.
The pharmacology explains the delivery form. The peptide is far more stable than natural α-MSH, so it is delivered as a bioresorbable implant that releases it over days.
Two placebo-controlled pivotal trials, reported together in 2015, enrolled 168 adults with EPP. The table shows their results beside a later real-world cohort:
| Study | Patients | Result |
|---|---|---|
| U.S. pivotal trial | 94 | Median pain-free time in direct sunlight 69.4 hours with afamelanotide versus 40.8 hours with placebo (P = 0.04) |
| EU pivotal trial | 74 | Median 6.0 hours versus 0.8 hours (P = 0.005), with 77 phototoxic reactions versus 146 |
| Dutch real-world cohort | 117 patients | 98% stayed on treatment over a median 2.0 years of follow-up |
The most common adverse events in the pivotal trials were headache, nausea, nasopharyngitis, and back pain, and quality of life improved in both studies.
Is it FDA-approved?
Editor’s note
Status: FDA-approved peptide, sold as Scenesse, given as a subcutaneous implant
Category: FDA-approved · Primary body area: Skin & aging
Yes. The FDA approved afamelanotide in October 2019 as Scenesse, the first treatment in the United States shown to increase pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria. It had already been approved in the European Union in 2014. It remains the only FDA-approved drug that works by stimulating melanin for photoprotection.
What is afamelanotide prescribed for?
Afamelanotide is prescribed for adults with erythropoietic protoporphyria to increase the amount of time they can spend in the light without pain. EPP is a rare inherited disorder in which light exposure causes severe burning pain in the skin, which sharply limits daily life. Consensus guidelines from 2023 recommend afamelanotide for preventing phototoxic symptoms in EPP. It is not a cosmetic tanning product and is not approved for tanning or for any other condition.
Because it is an implant, it is administered by a healthcare provider rather than self-injected. The label advises a full-body skin examination twice a year, since the drug increases pigmentation and can darken existing moles, which makes routine skin monitoring important.
What are the side effects?
According to the prescribing information, the most common side effects are:
- Implant-site reactions
- Nausea
- Throat pain and cough
- Fatigue
- Skin hyperpigmentation and darkening of existing moles
- Dizziness or drowsiness
- Respiratory tract infection
- Skin irritation
The label also warns that serious hypersensitivity reactions, including anaphylaxis, have been reported with postmarket use.
Because afamelanotide increases skin pigmentation, the label calls for regular full-body skin exams so that moles and any suspicious lesions can be monitored over time.
Sources: FDA prescribing information for Scenesse (afamelanotide); the pivotal randomized controlled trials in the New England Journal of Medicine (Langendonk et al., 2015, DOI: 10.1056/NEJMoa1411481), indexed on PubMed; and FDA and published histories of the compound's development. This document is educational and does not constitute medical advice.
Registered human trials
3 registered human trials on ClinicalTrials.gov that we reviewed
Compare every peptide’s status in the peptide regulatory status database
More for Skin & aging
View all skin & aging peptides →- Cosmetic & topical Skin & aging
Acetyl-Hexapeptide-8
Argireline
Acetyl hexapeptide-8, sold in skincare as Argireline, is a synthetic peptide modeled on the nerve protein SNAP-25 and marketed as a topical, "Botox-like" way to soften the appearance of expression lines. In lab and small clinical studies it interferes with the SNARE complex that nerves use to trigger muscle contraction, and a 2013 randomized study found it reduced the appearance of peri-orbital wrinkles over four weeks. It is a cosmetic ingredient rather than a drug, so it does not require FDA approval, and its evidence is rated Moderate.
- Cosmetic & topical Skin & aging
Acetyl-Octapeptide-3
SNAP-8
Acetyl octapeptide-3, sold in skincare as SNAP-8, is a synthetic eight-amino acid peptide modeled on the nerve protein SNAP-25 and marketed as a stronger successor to Argireline for softening the appearance of expression lines. Like Argireline, it is designed to interfere with the SNARE complex that nerves use to trigger muscle contraction, but its own published human evidence is thin and comes mostly from the manufacturer. It is a cosmetic ingredient rather than a drug, so it does not require FDA approval, and its evidence is rated Low.
- Cosmetic & topical Skin & aging
Acetyl-Tetrapeptide-5
Eyeseryl
Acetyl tetrapeptide-5, sold in skincare as Eyeseryl, is a synthetic four-amino acid peptide used in eye creams to soften the look of under-eye bags and puffiness. It is thought to work in two ways, by easing the fluid buildup that makes the under-eye area look swollen and by limiting the glycation that stiffens collagen, though its published evidence comes almost entirely from the manufacturer. It is a cosmetic ingredient rather than a drug, so it does not require FDA approval, and its evidence is rated Low.
- FDA-approved Skin & aging
Bacitracin
Bacitracin is a cyclic polypeptide antibiotic produced by Bacillus bacteria that kills gram-positive bacteria by blocking the construction of their cell wall. It is best known as an over-the-counter topical ointment for preventing infection in minor cuts, scrapes, and burns, often combined with neomycin and polymyxin B in "triple antibiotic" products. It is widely available over the counter, but it is also a common cause of allergic skin reactions, and its injectable form was withdrawn over kidney-toxicity concerns.
- Cosmetic & topical Skin & aging
Carnosine
Carnosine is a naturally occurring dipeptide, made of the amino acids beta-alanine and histidine, used in skincare as an antioxidant ingredient. Laboratory and ex-vivo skin studies suggest it can neutralize reactive oxygen species and limit glycation, a process in which sugars stiffen skin proteins, which is the rationale for using it in products aimed at the appearance of aging skin. As of 2026, the evidence for topical carnosine is largely from lab and ex-vivo studies rather than large human appearance trials.
- Cosmetic & topical Skin & aging
Copper-Tripeptide-1
GHK-Cu
Copper tripeptide-1, often called GHK-Cu, is a three-amino acid peptide (glycine-histidine-lysine) bound to a copper ion and used in skincare for its proposed role in skin renewal. Laboratory and animal studies show it can signal cells to make collagen and other matrix components. Independent human evidence is thin. In a randomized trial of 13 patients after CO2 laser resurfacing, GHK-Cu skincare showed no significant difference in redness or skin quality in blinded evaluations, though patients rated their overall skin quality higher (p = 0.04). As of 2026 it is a cosmetic ingredient, not an FDA-approved drug.